The Study of Clinical and Biochemical Parameters in Assessing the Response to the Antiviral Therapy in the Chronic Viral Hepatitis B
| Autor: | Aritina Moroşanu, Alice Elena Ghenea, Mara Carsote, Anca-Loredana Udriștoiu, Anca Ungureanu, Alex-Ioan Salan, Adriana Turculeanu, Eugen Nicolae Țieranu, Andrei Ioan Drocaş, Corina Maria Vasile, Viorel Biciușcă, Vlad Pădureanu, Ramona Cioboată |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Medicine (General)
HBsAg interferon-alpha α-2a/b Viremia medicine.disease_cause Antiviral Agents Article Virus Polyethylene Glycols Serology 03 medical and health sciences R5-920 Hepatitis B Chronic 0302 clinical medicine Pegylated interferon antiviral therapy medicine Humans chronic hepatitis B Hepatitis B e Antigens Hepatitis B virus Hepatitis B Surface Antigens business.industry virus diseases General Medicine medicine.disease Treatment Outcome Real-time polymerase chain reaction HBeAg 030220 oncology & carcinogenesis DNA Viral Immunology 030211 gastroenterology & hepatology business medicine.drug |
| Zdroj: | Medicina Medicina, Vol 57, Iss 757, p 757 (2021) Volume 57 Issue 8 |
| ISSN: | 1648-9144 |
| Popis: | Background and Objectives: Hepatitis B virus infection remains a major public health concern. The interaction between hepatitis B virus (HBV) hepatitis B virus and the host inflammatory response is an important contributing factor driving liver damage and diseases outcomes. The management of chronic hepatitis B virus infection is an area of massive unmet clinical need worldwide. Our primary aim for this study was to evaluate biological response rates and sustained virological response in patients with chronic hepatitis B treated with Peg-IFN α-2a/b. The second aim of the study was the identification of metabolic changes and insulin resistance. Materials and Methods: We enrolled in this study 166 patients who fulfilled all inclusion and exclusion criteria. These treatment-naive patients with chronic HBV were treated with Pegylated Interferon α-2a/b. HBV infection was defined by the presence of HBV serological markers (HBsAg, anti-HBsAb, anti-HBcAb, HBeAg, anti HBeAb) by Enzyme-Linked Immuno Sorbent Assay (ELISA) and serum HBV-DNA levels were estimated by a commercially available quantitative polymerase chain reaction (PCR) assay. Results: Patients’ recovery progress has been evaluated by determining the following: age, gender biochemical tests alanine aminotransferase, aspartate aminotransferase serological assays for HBV serological markers (HBsAg, anti-HBsAc/Ab, anti-HBcAc/Ab, HBeAg, anti HBeAc/Ab) molecular tests to detect viral particles, testing for HBV DNA (PCR) to confirm the diagnosis and quantify the number of viral copies in the blood (viremia) liver ultrasound—performed through epigastric and intercostal approach (transversal and longitudinal sections). Conclusions: Our results indicated that only HOMA index values, that of fasting insulin, together with baseline HBV DNA, alanine aminotransferase values, mean blood glucose at the beginning of treatment may be predictive of the early viral response in chronic hepatitis B. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|